Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Beyond NT-proBNP: The Role of CA-125 in Assessing Congestion in Advanced Heart Failure
Session:
Sessão de Posters 55 - Congestão, instabilidade e marcadores prognósticos na insuficiência cardíaca avançada
Speaker:
Patrícia Bernardes
Congress:
CPC 2026
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Patrícia Bernardes; Sara Gonçalves; Jéni Quintal; Tatiana Duarte; Margarida Madeira; Ana Sousa; Crisálida Ferreira; Sofia Senhorinho; Andreia Soares; Dina Ferreira; Filipe Seixo
Abstract
<p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Introduction</span></strong><br /> <span style="font-family:"Calibri",sans-serif">Carbohydrate antigen 125 (CA-125), a glycoprotein traditionally used as a tumor marker, has recently emerged as a promising biomarker of systemic congestion in heart failure (HF). However, its prognostic and predictive value in advanced HF remains insufficiently characterized.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Purpose</span></strong></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><span style="font-family:"Calibri",sans-serif">To assess the relationship between CA-125, congestion burden, and clinical outcomes in advanced HF, and to determine whether CA-125 adds information beyond NT-proBNP.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Methods</span></strong><br /> <span style="font-family:"Calibri",sans-serif">We conducted a retrospective observational study including 94 outpatients</span> <span style="font-family:"Calibri",sans-serif">with advanced HF followed at our multidisciplinary HF unit between September 2020 and October 2025. Routine CA-125 measurement was introduced in April 2025 and was available for 60 patients who were alive and under follow-up at that time. Clinical data, biomarker levels, HF hospitalizations, urgent HF visits, and mortality were analysed. Advanced HF was defined according to the 2018 Heart Failure Association of the European Society of Cardiology position statement.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><span style="font-family:"Calibri",sans-serif"><strong>Results</strong><br /> The subgroup with CA-125 measurements comprised 60 patients (mean age 71 ± 13.6 years; 65% male). Mean follow-up was 19.0 ± 9.5 months, and 90% were in NYHA class III–IV. Comorbidities were common: hypertension (70%), diabetes mellitus (47%), chronic kidney disease (42%), and obesity (37%). Ischaemic cardiomyopathy accounted for 48% of cases. Median CA-125 was 65 U/mL (IQR 16–143) and median NT-proBNP 5174 pg/mL (IQR 2085–15 565). CA-125 correlated with HF hospitalizations (p = 0.045), urgent HF visits (p = 0.032), and NT-proBNP (Spearman ρ = 0.419, p < 0.001). The correlation with NT-proBNP was stronger in patients with right or biventricular HF (ρ = 0.554, p = 0.003) than in those with left-sided HF (ρ = 0.305, p = 0.084). No significant association with mortality was observed (p = 0.466). In multivariable Poisson regression, CA-125 independently predicted the number of HF decompensations (IRR 1.003, 95% CI 1.002–1.004, p < 0.001), meaning that each 100 U/mL increase in CA-125 corresponded to an approximately 35% higher rate of HF decompensations.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Conclusions</span></strong><br /> <span style="font-family:"Calibri",sans-serif">In this cohort of advanced HF, elevated CA-125 was strongly associated with congestion burden and decompensation frequency. Its correlation with NT-proBNP—particularly in right/biventricular HF—supports a complementary role in congestion assessment. CA-125 is a simple, inexpensive biomarker providing additive prognostic information when interpreted alongside NT-proBNP.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site